News & Media

Press Releases

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism Download a PDF copy of this press release: EN FR Lyon, …

Download a PDF: EN or FR

Amolyt Pharma Announces Research Collaboration with PeptiDream

Amolyt Pharma Announces Research Collaboration with PeptiDream Download a PDF copy of this press release: EN FR Amolyt and Peptidream will collaborate to optimize and …

Download a PDF: EN or FR

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601, for Hypoparathyroidism

LYON, France, and NEWTON, MA, October 14, 2020 (GLOBE NEWSWIRE) — Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.

Download a PDF: EN or FR

Presentations

  • All PRESENTATIONS
  • AZP-3404
  • AZP-3601
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3404
  • AZP-3601
AZP-3404

Improved Glucose Metabolism and Decreased Weight Gain in Leptin-Resistant, IGFBP2-Deficient, db/db Mice Induced by AZP-3404, a 9-Amino Acid Analog of IGFBP2. e-ECE 2021.

Download a PDF: EN or FR
AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Download a PDF: EN or FR
AZP-3601

cHP Natural History Study: ISPOR Poster

Download a PDF: EN or FR
AZP-3404

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

Download a PDF: EN or FR
AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Download a PDF: EN or FR
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Download a PDF: EN or FR
AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Download a PDF: EN or FR

Upcoming events

Date: September 29 – October 3, 2021 (Virtual)

Learn more about the conference »

Date: October 2021

Date: October 1-4, 2021 (Toronto)

Learn more about the conference »

Date: October 13-16, 2021 (Le Havre)

Learn more about the conference »

Date: October 19-22, 2021 (Denver, CO)

Learn more about the conference »

Date: November 2-7, 2021 (San Diego, CA)

Learn more about the conference »

Date: November 1, 2021

Social Updates

TWITTER

Scroll to Top